Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Vistagen Therapeutics, Inc. (VTGN) Shareholders

Core Viewpoint - Vistagen Therapeutics, Inc. is facing a class action securities lawsuit due to alleged securities fraud related to its Phase 3 PALISADE-3 trial of fasedienol, which did not meet its primary endpoint, leading to a significant decline in stock price [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors affected by alleged securities fraud between April 1, 2024, and December 16, 2025 [1]. - Defendants allegedly made positive statements while concealing adverse facts about the Phase 3 PALISADE-3 trial of fasedienol, which is intended for treating social anxiety disorder [2]. - Following the announcement that the trial did not show statistically significant improvement, Vistagen's stock price plummeted from $4.36 to $0.86, a decline of over 80% [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until March 16, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a strong track record, having secured hundreds of millions for shareholders and being recognized as a top securities litigation firm in the U.S. for seven consecutive years [4].